A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC

NCT ID: NCT04844983

Last Updated: 2024-03-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 44 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-05-18
• Study Completion Date: 2022-12-06

Brief Summary

The purpose of this trial is to evaluate safety, tolerability and efficacy of various doses of STP705 administered as intralesional injection in subjects with cutaneous squamous cell carcinoma (in situ) skin cancer (isSCC).

Detailed Description

This is a two-part, double-blind, randomized, placebo-controlled study designed to evaluate safety and efficacy of various doses of STP705 administered as an intralesional injection in subjects with isSCC.

A total of up to 100 eligible subjects will be enrolled. Enrolled subjects will be randomly allocated to receive STP705 or placebo injection once weekly for 6 weeks.

After 6 weeks, the lesion will be excised.

In part 1 (dose ranging study): 40 subjects will be randomized to receive 1 of the 3 STP705 doses or placebo.

An interim analysis will be done after all subjects have completed end of treatment (EOT) visits to determine 2 selected dose levels of STP705 to be used in part of the study.

In part 2: 60 additional subjects will be randomized to receive 1 of the 2 selected doses (from part 1) or placebo.

In both parts at the End of Treatment (EOT), the lesion will be excised.

Conditions

Squamous Cell Carcinoma in Situ

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Part 1: Arm A

STP705 30 μg dose, intralesional injection, given once a week for 6 weeks.

Group Type: EXPERIMENTAL

STP705

Intervention Type: DRUG

The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.

Part 1: Arm B

STP705 60 μg dose, intralesional injection, given once a week for 6 weeks.

Group Type: EXPERIMENTAL

STP705

Intervention Type: DRUG

The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.

Part 1: Arm C

STP705 90 μg dose, intralesional injection, given once a week for 6 weeks.

Group Type: EXPERIMENTAL

STP705

Intervention Type: DRUG

The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.

Part 1: Arm D

Placebo (normal saline), intralesional injection, given once a week for 6 weeks.

Group Type: OTHER

Placebo Saline

Intervention Type: OTHER

Normal Saline

Part 2: Arm A, B or C

STP705 selected dose 1, intralesional injection, given once a week for 6 weeks.

Group Type: EXPERIMENTAL

STP705

Intervention Type: DRUG

The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.

Part 2: Arm A or B or C

STP705 selected dose 2, intralesional injection, given once a week for 6 weeks.

Group Type: EXPERIMENTAL

STP705

Intervention Type: DRUG

The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.

Part 2: Arm D

Placebo (normal saline), intralesional injection, given once a week for 6 weeks.

Group Type: OTHER

Placebo Saline

Intervention Type: OTHER

Normal Saline

Interventions

STP705

The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.

Intervention Type: DRUG

Placebo Saline

Normal Saline

Intervention Type: OTHER

Other Intervention Names

STP705 Powder for Injection

Eligibility Criteria

Inclusion Criteria

1. Male or female adult ≥ 18 years of age.

2. Primary, histologically confirmed trunk or extremity (non- anogenital/-facial/-scalp) isSCC lesion suitable for excision with a minimum diameter of 0.5 cm and with a maximum diameter of 2.0 cm.

3. Histological diagnosis made no more than 6 months prior to the screening visit.

4. No other dermatological disease in the isSCC target site or surrounding area, which in the opinion of the investigator, could interfere with the study.

5. Willing to refrain from using non-approved lotions or creams on the target site and surrounding area during the treatment period.

6. Willing to refrain from exposure to excessive direct sunlight or ultraviolet light and to avoid the use of tanning parlors for the duration of the study.

7. Laboratory values for the tests (listed in the Study Schedule) within the reference ranges as defined by the central laboratory, or "out of range" test results that are clinically acceptable to the investigator.

8. Ability to follow study instructions and likely to complete all study requirements.

9. Written informed consent obtained, including consent for tissue to be examined and stored by the Central Histology Lab.

10. Written consent to allow photographs of the target isSCC lesion to be used as part of the study data and documentation.

11. For females of childbearing potential, a negative pregnancy test at screening and using an acceptable form of birth control (oral / implant/ injectable/ transdermal contraceptives, intrauterine device, condom, diaphragm, abstinence, or a monogamous relationship with a partner who has had a vasectomy).

Exclusion Criteria

1. Pregnant, lactating, or planning to become pregnant.

2. Presence of known or suspected systemic cancer.

3. Histological evidence of severe squamous metaplasia, infiltrative, desmoplastic or micronodular growth patterns in the biopsy specimen.

4. History of recurrence of the target isSCC lesion.

5. Concurrent disease or treatment that suppresses the immune system.

6. Patients with baseline QTC > 480 msec using Frederica's formula.

7. Chronic medical condition that in the judgment of the investigator(s) would interfere with the performance of the study or would place the patient at undue risk.

8. Known sensitivity to any of the ingredients in the study medication including an allergy to trehalose.

9. Use of a tanning bed or other excessive or prolonged exposure to ultraviolet light or direct sunlight during the study.

10. Treatment with systemic chemotherapeutic agents within the 6 months prior to the screening visit.

11. Use of systemic retinoids within the 6 months prior to the screening period.

12. Treatment with systemic immunomodulators or immunosuppressants within the 6 months prior to the screening period.

13. Use of topical immunomodulators within 2 cm of the target isSCC lesion within the 4 weeks prior to the screening period.

14. Treatment with the following topical agents within 2 cm of the target isSCC lesion within the 4 weeks prior to the screening visit: aminolevulinic acid, 5-fluorouracil, corticosteroids, retinoids, diclofenac, ingenol mebutate, or imiquimod.

15. Treatment with liquid nitrogen, surgical excision or curettage within 2 cm of the target isSCC lesion during the 4 weeks prior to the screening visit.

16. Evidence of current chronic alcohol or drug abuse.

17. Current enrollment in an investigational drug or device study or participation in such a study within 4 weeks of the screening visit.

18. In the investigator's opinion, evidence of unwillingness, or inability to follow the restrictions and requirements of the protocol and complete the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sirnaomics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mark Nestor, MD

Role: PRINCIPAL_INVESTIGATOR

Center for Clinical and Cosmetic Research

David Goldberg

Role: PRINCIPAL_INVESTIGATOR

Schweiger Dermatology Group

Michael Gold, MD

Role: PRINCIPAL_INVESTIGATOR

Tennessee Clinical Research

Edward Lain, MD

Role: PRINCIPAL_INVESTIGATOR

Austin Institute for Clinical Research

Kenneth Beer, MD

Role: PRINCIPAL_INVESTIGATOR

Research Institute of the Southeast LLC

Brenda LaTowsky, MD

Role: PRINCIPAL_INVESTIGATOR

Investigate MD

Edward Primka, MD

Role: PRINCIPAL_INVESTIGATOR

Dermatology Associates of Knoxville

Girish Munavalli, MD

Role: PRINCIPAL_INVESTIGATOR

Dermatology, Laser and Vein Specialists of the Carolinas

Brian Jiang, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, San Diego

Megan Couvillion, MD

Role: PRINCIPAL_INVESTIGATOR

SBA Dermatology

Mark Ling, MD

Role: PRINCIPAL_INVESTIGATOR

Medaphase Inc

Locations

Investigate MD

Scottsdale, Arizona, United States

Center for Clinical and Cosmetic Research

Aventura, Florida, United States

Research Institute of the Southeast LLC

West Palm Beach, Florida, United States

Dermatology, Laser and Vein Specialists of the Carolinas

Charlotte, North Carolina, United States

Dermatology Associates of Knoxville

Knoxville, Tennessee, United States

Tennessee Clinical Research

Nashville, Tennessee, United States

Austin Institute for Clinical Research

Pflugerville, Texas, United States

Countries

United States

Other Identifiers

SRN-705-008

Identifier Type: -

Identifier Source: org_study_id